Smith+Nephew announced that the American Medical Association’s Current Procedural Terminology (CPT) Editorial Panel has designated a CPT code for its CARTIHEAL AGILI-C Cartilage Repair Implant, effective January 1, 2027.
The CPT code recognizes the clinical significance and growing adoption of the CARTIHEAL Implant, a single-stage, off-the-shelf solution for treating cartilage and osteochondral defects in the knee, including in patients with mild to moderate osteoarthritis (OA). The implant received Breakthrough Device Designation from the U.S. Food and Drug Administration and is the only FDA-approved device for this indication, according to Smith+Nephew.
The CARTIHEAL Implant demonstrated an 87% reduction in the relative risk of total knee arthroplasty or osteotomy at 4 years compared to microfracture or debridement, according to data published from a multicenter randomized controlled trial.
The new code designation will streamline reimbursement processes for providers and payers, supporting the integration of the CARTIHEAL Implant into standard clinical practice. It also reflects the AMA’s recognition of the procedure’s clinical efficacy, safety, and widespread physician adoption.
“This code represents a critical milestone on our journey to enable access to patients that can benefit from the CARTIHEAL Implant,” said Christie Van Geffen, SVP Global Sports Medicine Marketing for Smith+Nephew.
Smith+Nephew announced that the American Medical Association's Current Procedural Terminology (CPT) Editorial Panel has designated a CPT code for its CARTIHEAL AGILI-C Cartilage Repair Implant, effective January 1, 2027.
The CPT code recognizes the clinical significance and growing adoption of the CARTIHEAL Implant, a single-stage,...
Smith+Nephew announced that the American Medical Association’s Current Procedural Terminology (CPT) Editorial Panel has designated a CPT code for its CARTIHEAL AGILI-C Cartilage Repair Implant, effective January 1, 2027.
The CPT code recognizes the clinical significance and growing adoption of the CARTIHEAL Implant, a single-stage, off-the-shelf solution for treating cartilage and osteochondral defects in the knee, including in patients with mild to moderate osteoarthritis (OA). The implant received Breakthrough Device Designation from the U.S. Food and Drug Administration and is the only FDA-approved device for this indication, according to Smith+Nephew.
The CARTIHEAL Implant demonstrated an 87% reduction in the relative risk of total knee arthroplasty or osteotomy at 4 years compared to microfracture or debridement, according to data published from a multicenter randomized controlled trial.
The new code designation will streamline reimbursement processes for providers and payers, supporting the integration of the CARTIHEAL Implant into standard clinical practice. It also reflects the AMA’s recognition of the procedure’s clinical efficacy, safety, and widespread physician adoption.
“This code represents a critical milestone on our journey to enable access to patients that can benefit from the CARTIHEAL Implant,” said Christie Van Geffen, SVP Global Sports Medicine Marketing for Smith+Nephew.
Copy to clipboard 
